Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2012

View Archived Issues

Phase II ALS trial set to begin with fingolimod

Self-propelled microrockets with drug delivery potential function in acidic environments

Exelixis synthesizes lysophospholipid S1P1 receptor antagonists with antitumor potential

China Medical University presents new sodium/iodide cotransporter proteins

Nippon Chemiphar patents novel P2X4 receptor antagonists

Russian team patents novel interferon alfa-2b conjugates

Japanese researchers present new protein kinase inhibitors

Dako and Amgen begin new collaboration

CHMP issues opinion on Humira in ulcerative colitis

Fuso Pharmaceutical synthesizes new agents to treat cancer

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized by Sanofi

EMA adopts scientific opinion on Pyramax

Pivotal Takeda trial meets primary endpoints

Studies clarify genetic basis of Bartsocas-Papas syndrome

Critical Pharma and U.K. university team up to develop nasal spray for osteoporosis

FDA accepts Actemra sBLA for review

Genticel completes recruitment in phase Ib trial of HPV vaccine

Redevant launched in Mexico

GSK exercises exclusive license option for compounds developed with Galapagos

CHMP requests additional information on Glybera

Amsterdam Molecular Therapeutics' assets and liabilities to be acquired by uniQure

Threshold Pharmaceuticals' phase IIb study in pancreatic cancer meets primary endpoint

Novel inhibitor of V600-mutant B-raf shows antitumor activity in animal models

UMN Pharma licenses novel norovirus and rotavirus combination vaccine candidate

FDA places clinical hold on Capesaris

Innocoll announces successful end-of-phase II meeting with FDA for XaraColl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...